



(11) **EP 2 735 568 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07H 21/00 ^(2006.01) **C12N 15/11** ^(2006.01)
C07H 19/16 ^(2006.01) **C07H 19/20** ^(2006.01)

(48) Corrigendum issued on:
27.09.2017 Bulletin 2017/39

(45) Date of publication and mention
of the grant of the patent:
02.08.2017 Bulletin 2017/31

(21) Application number: **13186973.7**

(22) Date of filing: **10.05.2007**

(54) **Oligonucleotide analogs having cationic intersubunit linkages**

Oligonucleotid-analoge mit kationischen Zwischenuntereinheitsverknüpfungen

Analogues d'oligonucléotides ayant des liaisons internes de sous-unités cationiques

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE
SI SK TR

(30) Priority: **10.05.2006 US 432216**
10.05.2006 US 432031
10.05.2006 US 432155
10.05.2006 US 431968
11.05.2006 US 433257
11.05.2006 US 799976 P
11.05.2006 US 800145 P
11.05.2006 US 433213
11.05.2006 US 433214
11.05.2006 US 433033
11.05.2006 US 433840
11.05.2006 US 433724
11.05.2006 US 800076 P
11.05.2006 US 800120 P
08.09.2006 US 518058
08.09.2006 US 517757
08.11.2006 US 595161
07.03.2007 US 715572

(43) Date of publication of application:
28.05.2014 Bulletin 2014/22

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
07861308.0 / 2 024 499

(73) Proprietor: **Sarepta Therapeutics, Inc.**
Cambridge, MA 02142 (US)

(72) Inventors:
• **Weller, Dwight D.**
Corvallis, OR 97330 (US)
• **Hassinger, Jed N.**
Philomath, OR 97370 (US)
• **Cai, Bao**
Corvallis, OK 97330 (US)

(74) Representative: **D Young & Co LLP**
120 Holborn
London EC1N 2DY (GB)

(56) References cited:
US-A- 5 185 444

EP 2 735 568 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- **SUMMERTON ET AL: "Morpholino antisense oligomers: design, preparation, and properties", SENSE & NUCLEIC ACID DRUG DEVELOPMENT, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 7, 1 January 1997 (1997-01-01), pages 187-195, XP002136176, ISSN: 1087-2906**